CBD Pharmacology

CBD pharmacology is an ever-evolving field of research that studies the effects of CBD on various diseases and conditions.

Therapeutic potentials for this cannabinoid compound are limitless. But they can only be realized with further research and advancements in our understanding of how CBD works on a cellular level to produce desired outcomes depending upon what disorders or ailments you want relief from!

First of all, let’s talk about CBD itself.

Cannabidiol (CBD) is a principal phytocannabinoid constituent of cannabis that has potential therapeutic applications with no clinically relevant toxicity to date. And it has no psychoactive effects.

CBD is one of over 120 identified cannabinoids found in the cannabis plant. The only psychoactive cannabinoid is ∆9-tetrahydrocannabinol (∆9-THC).

THC is still considered a class 1 narcotic by the DEA. However, hemp plant strains can be grown to .03% THC (with no psychoactive effects).

Research on CBD and its potential in Pharmaceutical medicine

CBD has been known since 1940. Its application to be replicated and produced to replace many pharmaceutical medications is new.

One such company researching the pharmaceutical uses of CBD is Artelo BioSciences.

Artelo BioSciences Inc. has developed a patent novel CBD composition called ART12.11. This is a patented process so CBD may be created as a cocrystal.

Of course, now you’re wondering what a cocrystal is? Cocrystallization is a proven pharmaceutical development strategy and follows FDA guidance for chemicals with properties like CBD.

Why turn CBD into pharmaceutical medicines?

One limit to today’s CBD extracts lies in its instability, dissolution, and bioavailability.

There are also inconsistencies present in the manufacturing process of CBD.

These inconsistencies are referred to as polymorphism.

Polymorphism affects the quality, safety, and efficacy of a drug product.

Research into polymorphism and CBD is incredibly important.

It is hoped that solid research will lead to full FDA approval of CBD as a regulated safe, and effective drug that helps either relieve symptoms from or cures numerous types of diseases and disorders.

The engineering of the crystalline structure has been around for decades and is a well-practiced pharmaceutical strategy. Read more about the Regulatory Classification of Pharmaceutical Co-Crystals Guidance for Industry.

So why not allow CBD extraction labs to keep doing a simple extraction process like they’re currently doing?

Because of inconsistent results from each extraction lab and the different strains of cannabis being tested. By streamlining the manufacturing process of CBD research and data compiled by pharmaceutical entities. The CBD industry can present in a convincing and uniform way to the FDA unifying standards.

  • Efficacy
  • Greater consistency in products
  • Better bioavailability
  • No polymorphism
  • Solid dosage formulation

The only current drug approved for use using cannabis is Epidiolex which is used for the treatment of two types of seizures in young adults.

Perhaps one day we will have safe reliable medicines a new breed if you will of treating disease and disorders in a wholesome and synergetic way.

Many people are regretting the day pharmaceutical companies will start muscling the little CBD producers out. This is a reality we must all face.

Perhaps there will be a balance struck between pharmaceutical CBD and boutique CBD allowed to co-exist. It’s up to us in the industry to speak up for our goals and wishes and work together for FDA approval of this wonderful medicine that comes from such an amazing and beautiful plant.

One thing for sure is without full FDA approval the CBD industry will languish and many boutique producers will lose money and go out of business sooner or later.

--

--

Get the Medium app

A button that says 'Download on the App Store', and if clicked it will lead you to the iOS App store
A button that says 'Get it on, Google Play', and if clicked it will lead you to the Google Play store